Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology - 1 May 2018

Moschetti Viktoria, Kim Maria, Sand Michael, Wunderlich Glen, Andersen Grit, Feifel Ulrich, Jang In-Jin, Timmer Wolfgang, Rosenbrock Holger, Boland Katja

Abstract excerpt

Safety, tolerability and pharmacokinetics of BI 409306, a potent and selective phosphodiesterase 9A inhibitor, were assessed in healthy subjects in three Phase I, within-dose group, double-blind trials. Trial 1 randomised young and elderly subjects to receive BI 409306 25, 50, 100 mg, placebo once daily (OD) or BI 409306 50 mg twice daily (young) for 14 days. Trial 2 randomised young poor metabolisers (PM) of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aging
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Administration Schedule

Share to Healthy Volunteers

Share to Phosphodiesterase Inhibitors

Share to Pyrazoles

Share to Pyrimidines

Source

Identifiers

PMID: 29567399
DOI: 10.1016/j.euroneuro.2018.01.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.PMID 29567399Read ↗

Safety and pharmacokinetic profile of pretomanid (PA-824) in healthy Chinese participants: Results of a phase I single dose escalation studySemantic proximity Read ↗

Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype.Semantic proximity Read ↗

A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers.Semantic proximity Read ↗

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of mocravimod in Healthy VolunteersSemantic proximity Read ↗

Pharmacokinetics of tenatoprazole, a newly synthesized proton pump inhibitor, in healthy male Caucasian volunteers.Semantic proximity Read ↗

Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes.Semantic proximity Read ↗

Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects.Semantic proximity Read ↗

Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers.Semantic proximity Read ↗

Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.Semantic proximity Read ↗

Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.Semantic proximity Read ↗

Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.Semantic proximity Read ↗

Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent ParticipantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.